ArticleCirculation reports2026
Association of Myocardial Degeneration With Delayed Recovery of Left Ventricular Function in Atrial Fibrillation-Induced Cardiomyopathy.
Article in Circulation reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Atrial fibrillation-induced cardiomyopathy (AF-CM) is a secondary cardiomyopathy characterized by recovery of left ventricular (LV) dysfunction after restoration of sinus rhythm from atrial fibrillation (AF); however, the pathological evidence of AF-CM remains limited. Methods and Results: We retrospectively analyzed AF-CM patients who underwent both endomyocardial biopsy (EMB) from the right ventricle and catheter ablation (CA) for AF at Kyushu University Hospital between 2014 and 2023. We investigated the relationships between histological features and the recovery process of LV function in AF-CM after CA for AF. Recovery of LV ejection fraction (EF) was defined as an improvement ≥15%. EMB specimens were evaluated for myocardial fibrosis, cytoplasmic vacuolization, and nuclear expression of phosphorylated histone H2A variant X (γ-H2A.X) and poly(ADP-ribose) (PAR). Among 23 patients, the median time from CA to LVEF recovery was 145 days [90-220], and 83% achieved an LVEF ≥50%. Greater myocardial fibrosis, cytoplasmic vacuolization, and higher nuclear expression of γ-H2A.X and PAR were associated with delayed LVEF recovery (r=0.43, 0.42, 0.49, and 0.47, respectively). AF-CM severity scores derived from these histological features demonstrated associations with LVEF recovery time (R Conclusions: In AF-CM patients undergoing CA, severe myocardial degeneration and DNA damage were associated with delayed recovery of LV systolic function.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.